Online inquiry

IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6041MR)

This product GTTS-WQ6041MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Giant cell arteritis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6041MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11728MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ11597MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ3524MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ15749MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ10370MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ9206MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ4203MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ10658MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3819253
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW